Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
AMES, Iowa, June 20, 2018 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced that updated data for patients with diffuse intrinsic pontine glioma (DIPG) from NLG2105, a...
-
AMES, Iowa, May 30, 2018 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) announced today that the company will present at the Jefferies 2018 Global Healthcare Conference on Thursday,...
-
AMES, Iowa, May 16, 2018 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced that abstracts from two Phase 2 studies of indoximod, used in combination with other agents,...
-
AMES, Iowa, May 03, 2018 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today reported consolidated financial results for the first quarter 2018 and reviewed recent highlights and...
-
AMES, Iowa, May 01, 2018 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced the appointment of Matthew L. Sherman, M.D. to the Company's Board of Directors. In...
-
AMES, Iowa, April 30, 2018 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) announced today that the company will participate in the following investor conferences: Deutsche Bank 43rd...
-
AMES, Iowa, April 25, 2018 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today reported that two abstracts pertaining to the company's indoximod program will be presented at...
-
AMES, Iowa, April 20, 2018 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced that it will release its first quarter 2018 financial results on Thursday, May 3, 2018. The...
-
AMES, Iowa, April 15, 2018 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK), today reported initial data from NLG2105, a Phase 1 study evaluating indoximod, its IDO pathway inhibitor,...
-
AMES, Iowa, April 06, 2018 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced a review of its clinical programs. This morning’s announcement by Incyte and Merck on...